Business Context and Reporting Period
This Form 8-K is a current report filed by Pieris Pharmaceuticals, Inc. (not Palvela Therapeutics, Inc., as noted in the metadata) on September 10, 2018, covering events occurring on September 7, 2018. The filing reports the election of a new director to the Company's Board of Directors.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
The primary material change reported is the appointment of Peter Kiener, D.Phil. to the Board of Directors as a Class I Director, with a term expiring at the 2021 annual meeting of stockholders. Dr. Kiener brings significant experience from roles at Sucampo, Ambrx Inc., Zyngenia Inc., MedImmune LLC, and Bristol-Myers Squibb.
Guidance, Outlook, and Compensation
While no financial guidance is provided, the filing details the compensatory arrangements for the new director:
- Stock Option: A non-statutory stock option to purchase up to 30,000 shares of common stock, to be granted at the next regularly scheduled Board meeting. The exercise price will equal the closing price on the grant date.
- Vesting Schedule: The option will vest in equal quarterly installments following the grant date, contingent on continued service.
- Cash Retainer: An annual cash retainer of $35,000 for service as a non-employee director.
- Indemnification: Dr. Kiener will enter into a standard indemnification agreement covering expenses, judgments, fines, and settlement amounts arising from his service.
The filing states there are no undisclosed transactions in which Dr. Kiener has a material interest.
Investor Verification Checklist
- Verify the exact grant date and exercise price of the 30,000-share stock option once the next Board meeting occurs.
- Review the Company's Non-Employee Director Compensation Policy to confirm the standard terms for other directors.
- Confirm the absence of any related-party transactions involving Dr. Kiener as disclosed in the filing.
- Note that the metadata company name "Palvela Therapeutics, Inc." appears to be incorrect; the filing is for Pieris Pharmaceuticals, Inc.